• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Qiming Corporate Gp Vi, Ltd.

    4/22/26 4:16:41 PM ET
    $ALMR
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $ALMR alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Qiming Corporate GP VI, Ltd.

    (Last)(First)(Middle)
    C/O MAPLES CORPORATE SERVICES LIMITED
    PO BOX 309

    (Street)
    UGLAND HOUSEGRAND CAYMANKY1-1104

    (City)(State)(Zip)

    CAYMAN ISLANDS

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    Alamar Biosciences, Inc. [ ALMR ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    DirectorX10% Owner
    Officer (give title below)Other (specify below)
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    04/20/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    XForm filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Class B Common Stock04/20/2026C185,163A(1)(2)185,163ISee footnote(3)
    Class B Common Stock04/20/2026C6,881,410A(1)(2)6,881,410ISee footnote(4)
    Class B Common Stock04/20/2026C1,605,645A(1)1,605,645ISee footnote(5)
    Class B Common Stock04/20/2026C1,922,329A(1)1,922,329ISee footnote(6)
    Class B Common Stock04/20/2026J(7)185,163D(7)0ISee footnote(3)
    Class B Common Stock04/20/2026J(7)6,881,410D(7)0ISee footnote(4)
    Class B Common Stock04/20/2026J(7)1,605,645D(7)0ISee footnote(5)
    Class B Common Stock04/20/2026J(7)1,922,329D(7)0ISee footnote(6)
    Common Stock04/20/2026J(7)185,163A(7)185,163ISee footnote(3)
    Common Stock04/20/2026J(7)6,881,410A(7)6,881,410ISee footnote(4)
    Common Stock04/20/2026J(7)1,605,645A(7)1,605,645ISee footnote(5)
    Common Stock04/20/2026J(7)1,922,329A(7)1,922,329ISee footnote(6)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Series A-3 Preferred Stock(1)04/20/2026C172,328 (1) (1)Class B Common Stock71,268$00ISee footnote(3)
    Series A-3 Preferred Stock(1)04/20/2026C6,404,332 (1) (1)Class B Common Stock2,648,607$00ISee footnote(4)
    Series A-4 Preferred Stock(1)04/20/2026C154,425 (1) (1)Class B Common Stock63,864$00ISee footnote(3)
    Series A-4 Preferred Stock(1)04/20/2026C5,738,971 (1) (1)Class B Common Stock2,373,437$00ISee footnote(4)
    Series B Preferred Stock(2)04/20/2026C113,625 (2) (2)Class B Common Stock50,031$00ISee footnote(3)
    Series B Preferred Stock(2)04/20/2026C4,222,738 (2) (2)Class B Common Stock1,859,366$00ISee footnote(4)
    Series C Preferred Stock(1)04/20/2026C3,882,451 (1) (1)Class B Common Stock1,605,645$00ISee footnote(5)
    Series C Preferred Stock(1)04/20/2026C4,648,194 (1) (1)Class B Common Stock1,922,329$00ISee footnote(6)
    1. Name and Address of Reporting Person*
    Qiming Corporate GP VI, Ltd.

    (Last)(First)(Middle)
    C/O MAPLES CORPORATE SERVICES LIMITED
    PO BOX 309

    (Street)
    UGLAND HOUSEGRAND CAYMANKY1-1104

    (City)(State)(Zip)

    CAYMAN ISLANDS

    (Country)

    Relationship of Reporting Person(s) to Issuer
    DirectorX10% Owner
    Officer (give title below)Other (specify below)
    1. Name and Address of Reporting Person*
    Qiming Managing Directors Fund VI, L.P.

    (Last)(First)(Middle)
    C/O MAPLES CORPORATE SERVICES LIMITED
    PO BOX 309

    (Street)
    UGLAND HOUSEGRAND CAYMANKY1-1104

    (City)(State)(Zip)

    CAYMAN ISLANDS

    (Country)

    Relationship of Reporting Person(s) to Issuer
    DirectorX10% Owner
    Officer (give title below)Other (specify below)
    1. Name and Address of Reporting Person*
    Qiming Venture Partners VI, L.P.

    (Last)(First)(Middle)
    C/O MAPLES CORPORATE SERVICES LIMITED
    PO BOX 309

    (Street)
    UGLAND HOUSEGRAND CAYMANKY1-1104

    (City)(State)(Zip)

    CAYMAN ISLANDS

    (Country)

    Relationship of Reporting Person(s) to Issuer
    DirectorX10% Owner
    Officer (give title below)Other (specify below)
    1. Name and Address of Reporting Person*
    Qiming GP VIII, LLC

    (Last)(First)(Middle)
    C/O MAPLES CORPORATE SERVICES LIMITED
    PO BOX 309

    (Street)
    UGLAND HOUSEGRAND CAYMANKY1-1104

    (City)(State)(Zip)

    CAYMAN ISLANDS

    (Country)

    Relationship of Reporting Person(s) to Issuer
    DirectorX10% Owner
    Officer (give title below)Other (specify below)
    1. Name and Address of Reporting Person*
    Qiming Venture Partners VIII Investments, LLC

    (Last)(First)(Middle)
    C/O MAPLES CORPORATE SERVICES LIMITED
    PO BOX 309

    (Street)
    UGLAND HOUSEGRAND CAYMANKY1-1104

    (City)(State)(Zip)

    CAYMAN ISLANDS

    (Country)

    Relationship of Reporting Person(s) to Issuer
    DirectorX10% Owner
    Officer (give title below)Other (specify below)
    1. Name and Address of Reporting Person*
    Qiming GP VIII-HC, LLC

    (Last)(First)(Middle)
    C/O MAPLES CORPORATE SERVICES LIMITED
    PO BOX 309

    (Street)
    UGLAND HOUSEGRAND CAYMANKY1-1104

    (City)(State)(Zip)

    CAYMAN ISLANDS

    (Country)

    Relationship of Reporting Person(s) to Issuer
    DirectorX10% Owner
    Officer (give title below)Other (specify below)
    1. Name and Address of Reporting Person*
    Qiming Venture Partners VIII-HC, L.P.

    (Last)(First)(Middle)
    C/O MAPLES CORPORATE SERVICES LIMITED
    PO BOX 309

    (Street)
    UGLAND HOUSEGRAND CAYMANKY1-1104

    (City)(State)(Zip)

    CAYMAN ISLANDS

    (Country)

    Relationship of Reporting Person(s) to Issuer
    DirectorX10% Owner
    Officer (give title below)Other (specify below)
    Explanation of Responses:
    1. Each share of the Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock converted into 0.4136 share of Class B Common Stock at the closing of the initial public offering. The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock had no expiration date.
    2. Each share of Series B Preferred Stock converted into 0.4403 share of Class B Common Stock at the closing of the initial public offering. The Series B Preferred Stock had no expiration date.
    3. These shares are held of record by Qiming Managing Directors Fund VI, L.P. ("Qiming Managing Directors"). Qiming Corporate GP VI, Ltd. ("Qiming Corporate") serves as the general partner of Qiming Managing Directors and may be deemed to have voting and dispositive power over the shares held by Qiming Managing Directors. Qiming Corporate disclaims beneficial ownership of such shares, except to the extent of its proportionate pecuniary interest therein.
    4. These shares are held of record by Qiming Venture Partners VI, L.P., ("Qiming Venture Partners VI"). Qiming Corporate, through one intermediary, serves as the indirect general partner of Qiming Venture Partners VI and may be deemed to have voting and dispositive power over the shares held by Qiming Venture Partners VI. Qiming Corporate disclaims beneficial ownership of such shares, except to the extent of its proportionate pecuniary interest therein.
    5. These shares are held of record by Qiming Venture Partners VIII Investments, LLC ("QVP VIII LLC"). Qiming GP VIII, LLC, through two parallel intermediaries, serves as the indirect general partner of QVP VIII LLC and may be deemed to have voting and dispositive power over the shares held by QVP VIII LLC. Qiming GP VIII, LLC disclaims beneficial ownership of such shares, except to the extent of its proportionate pecuniary interest therein.
    6. These shares are held of record by Qiming Venture Partners VIII-HC, L.P. ("QVP VIII-HC"). Qiming GP VIII-HC, LLC serves as the general partner of QVP VIII-HC and may be deemed to have voting and dispositive power over the shares held by QVP VIII-HC. Qiming GP VIII-HC, LLC disclaims beneficial ownership of such shares, except to the extent of its proportionate pecuniary interest therein.
    7. Each share of Class B Common Stock was automatically reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock.
    Qiming GP VIII, LLC By: /s/ Ho Man LAM/Authorized Signatory04/22/2026
    Qiming Venture Partners VIII Investments, LLC By: /s/ Ho Man LAM/Manager04/22/2026
    Qiming Corporate GP VI, Ltd By: /s/ Ho Man LAM/Authorized Signatory04/22/2026
    Qiming Managing Directors Fund VI, L.P. By: /s/ Ho Man LAM/Authorized Signatory04/22/2026
    Qiming Venture Partners VI, L.P. By: /s/ Ho Man LAM/Authorized Signatory04/22/2026
    Qiming GP VIII-HC, LLC By: /s/ Ho Man LAM/Authorized Signatory04/22/2026
    Qiming Venture Partners VIII-HC, L.P. By: /s/ Ho Man LAM/Authorized Signatory04/22/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $ALMR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALMR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ALMR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Qiming Corporate Gp Vi, Ltd.

    4 - Alamar Biosciences, Inc. (0002104204) (Issuer)

    4/22/26 4:16:41 PM ET
    $ALMR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 4 filed by Illumina Innovation Fund Ii Gp, L.L.C.

    4 - Alamar Biosciences, Inc. (0002104204) (Issuer)

    4/20/26 8:45:36 PM ET
    $ALMR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 4 filed by Chambers Rebecca

    4 - Alamar Biosciences, Inc. (0002104204) (Issuer)

    4/20/26 8:37:51 PM ET
    $ALMR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ALMR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $ALMR
    SEC Filings

    View All

    Precision Proteomics Leader Alamar Biosciences Lists on NASDAQ

    SHANGHAI, April 20, 2026 /PRNewswire/ -- Alamar Biosciences, a portfolio company of Qiming Venture Partners and a global leader in precision proteomics, successfully listed on the NASDAQ Stock Exchange on April 17th, 2026, Beijing Time. Alamar (NASDAQ:ALMR) issued shares at a price of $17 per share and opened at $22.6 per share with a market capitalization of approximately $1.5 billion. Qiming Venture Partners led Alamar's Series A financing in 2020 and continued to fund the company's development in the following Series B and Series C rounds. Before the company's IPO, Qiming Venture Partners held approximately 19.2% stake in Alamar and was one of its most important institutional investors.Fo

    4/20/26 3:09:00 AM ET
    $ALMR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SCHEDULE 13D filed by Alamar Biosciences Inc.

    SCHEDULE 13D - Alamar Biosciences, Inc. (0002104204) (Subject)

    4/23/26 4:24:00 PM ET
    $ALMR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SCHEDULE 13D filed by Alamar Biosciences Inc.

    SCHEDULE 13D - Alamar Biosciences, Inc. (0002104204) (Subject)

    4/23/26 1:57:55 PM ET
    $ALMR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form EFFECT filed by Alamar Biosciences Inc.

    EFFECT - Alamar Biosciences, Inc. (0002104204) (Filer)

    4/21/26 12:15:10 AM ET
    $ALMR
    Biotechnology: Laboratory Analytical Instruments
    Industrials